title: Attenuation of experimental hepatopulmonary syndrome in endothelin B receptor-deficient rats.
abstract: Experimental hepatopulmonary syndrome (HPS) after common bile duct ligation (CBDL) in rat is accompanied by increased lung vascular endothelial endothelin B (ETB) receptor expression and increased circulating levels of endothelin-1 (ET-1). The onset of HPS is hypothesized to be triggered by ET-1/ETB receptor activation of endothelial nitric oxide synthase (eNOS)-derived NO production in the pulmonary endothelium. However, whether functional pulmonary vascular ETB receptors are required for the development of experimental HPS is not defined. We evaluated the effects of vascular ETB receptor deficiency on the development of experimental HPS. The molecular and physiological alterations of HPS were compared in 2-wk CBDL wild-type and ETB receptor-deficient (transgenic sl/sl) rats. Relative to wild-type rats, basal hepatic and plasma ET-1 levels were elevated in sl/sl controls although, unlike wild-type animals circulating ET-1 levels, did not increase further after CBDL in sl/sl animals. In contrast to wild-type animals, ETB receptor-deficient rats did not develop increased Akt and eNOS expression and activation and did not develop gas exchange abnormalities of HPS after CBDL. There was a similar degree of pulmonary intravascular monocyte accumulation in both 2-wk CBDL sl/sl and wild-type animals. In conclusion, ETB receptor deficiency inhibits lung Akt/eNOS activation and prevents the onset of experimental HPS after CBDL. This effect is independent of inhibition of pulmonary intravascular monocyte accumulation. These results demonstrate that ET-1/ETB receptor signaling plays a key role in the initiation of experimental HPS.
authors.affiliation: Department of Internal Medicine, Liver Center, Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, AL, USA. Junlan.Zhang@uth.tmc.edu
authors.forename: Junlan
authors.initials: J
authors.lastname: Zhang
authors.forename: Yiqun
authors.initials: Y
authors.lastname: Ling
authors.forename: Liping
authors.initials: L
authors.lastname: Tang
authors.forename: Bao
authors.initials: B
authors.lastname: Luo
authors.forename: David M
authors.initials: DM
authors.lastname: Pollock
authors.forename: Michael B
authors.initials: MB
authors.lastname: Fallon
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D002779:Cholestasis; D019332:Endothelin-1 / Q000378:metabolism; D017353:Gene Deletion; D005786:Gene Expression Regulation; D020022:Genetic Predisposition to Disease; D051547:Heme Oxygenase-1 / Q000235:genetics / Q000378:metabolism; D020065:Hepatopulmonary Syndrome / Q000235:genetics*; D008099:Liver / Q000098:blood supply; D008297:Male; D052250:Nitric Oxide Synthase Type III / Q000235:genetics / Q000378:metabolism; D051058:Oncogene Protein v-akt / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D044023:Receptor, Endothelin B / Q000172:deficiency / Q000235:genetics* / Q000378:metabolism
chemical_list: D019332:Endothelin-1; D044023:Receptor, Endothelin B; D052250:Nitric Oxide Synthase Type III; D051547:Heme Oxygenase-1; D051058:Oncogene Protein v-akt